Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells

Published:2001-01 Issue:1 Volume:20 Page:34-47
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Balañá Maria Eugenia,Labriola Leticia,Salatino Mariana,Movsichoff Federico,Peters Giselle,Charreau Eduardo H,Elizalde Patricia V

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/1204050.pdf

Reference59 articles.

1. Backer JM, Myers MG, Sun XJ, Chen DJ, Schoelson SE, Mivalpeix M and White MF. . 1993 J. Biol. Chem. 268: 8204–8212.

2. Balañá ME, Lupu R, Labriola L, Charreau EH and Elizalde PV. . 1999 Oncogene 18: 6370–6379.

3. Baserga R. . 1995 Cancer Res. 55: 249–252.

4. Braunsberg H, Coldham NG, Learke RE, Cowan SK and Wong W. . 1987 Eur. J. Cancer Clin. Oncol. 23: 563–571.

5. Carraway KL and Cantley LC. . 1994 Cell 78: 5–8.

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. miR-770-5p-induced cellular switch to sensitize trastuzumab resistant breast cancer cells targeting HER2/EGFR/IGF1R bidirectional crosstalk;Turkish Journal of Biology;2024-04-26

2. Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer;Gynecologic Oncology;2023-03

3. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer;Gynecologic Oncology;2021-12

4. Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models;EMBO Molecular Medicine;2021-03-04

5. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor;Cancers;2020-08-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3